Related Experiment Video
Updated: Jul 17, 2026

Analytical Techniques for Assaying Nitric Oxide Bioactivity
Published on: June 18, 2012
Potency of authentic nitric oxide in inducing aortic relaxation
Qingtao Yan1, Qihui Liu, Jay L Zweier
1Davis Heart and Lung Research Institute, The Division of Cardiovascular Medicine, Department of Internal Medicine, and Biomedical Engineering Department, The Ohio State University, 473 W. 12th Avenue, Columbus, OH 43210, United States.
Abstract:
The reported EC(50) of vasorelaxation for authentic nitric oxide (NO) is from the nM to muM range. The cause of this large difference is undetermined. In this study, NO electrodes were used to monitor the actual NO concentration in the organ chamber during the recording of the relaxation of rat aortic rings. It was demonstrated that both the O(2) concentration in the solution and the rate of stirring the solution markedly affected the actual NO concentration, while the vasorelaxation response to NO was also changed with the composition of the buffer solution. It was observed that the apparent EC(50) of aortic relaxation for authentic NO is 340+/-40nM and 81+/-4nM in the conventional organ chamber containing Krebs-Ringer buffer bubbled with a high content (95% O(2)+5% CO(2)) and a low content (20% O(2)+5% CO(2)+75% N(2)) of O(2) gas mixture, respectively. The apparent EC(50) was further reduced to 45+/-2nM after the Krebs-Ringer buffer, a bicarbonate buffer, was replaced by a phosphate buffer solution bubbled with a low content of O(2) gas mixture (20% O(2)+80% N(2)) or with air. By using an organ chamber, which makes low concentrations of NO more stable in the solution, it was determined that the apparent EC(50) was 9.7+/-0.4nM and the threshold of NO concentration in dilating the aortas was approximately 0.3nM. This modified organ chamber will be useful for quantitatively measuring EC(50) of vasorelaxation for authentic NO under physiological and pathological conditions.
Related Concept Videos
Nitric Oxide Signaling Pathway
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antihypertensive Drugs: Vasodilators
Dose-Response Relationship: Potency and Efficacy
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

